Literature DB >> 28941296

Ghrelin receptor antagonism of hyperlocomotion in cocaine-sensitized mice requires βarrestin-2.

Krisztian Toth1, Lauren M Slosky1, Thomas F Pack1, Nikhil M Urs1, Peter Boone1, Lan Mao2, Dennis Abraham2, Marc G Caron1,2,3, Lawrence S Barak1.   

Abstract

The "brain-gut" peptide ghrelin, which mediates food-seeking behaviors, is recognized as a very strong endogenous modulator of dopamine (DA) signaling. Ghrelin binds the G protein-coupled receptor GHSR1a, and administration of ghrelin increases the rewarding properties of psychostimulants while ghrelin receptor antagonists decrease them. In addition, the GHSR1a signals through βarrestin-2 to regulate actin/stress fiber rearrangement, suggesting βarrestin-2 participation in the regulation of actin-mediated synaptic plasticity for addictive substances like cocaine. The effects of ghrelin receptor ligands on reward strongly suggest that modulation of ghrelin signaling could provide an effective strategy to ameliorate undesirable behaviors arising from addiction. To investigate this possibility, we tested the effects of ghrelin receptor antagonism in a cocaine behavioral sensitization paradigm using DA neuron-specific βarrestin-2 KO mice. Our results show that these mice sensitize to cocaine as well as wild-type littermates. The βarrestin-2 KO mice, however, no longer respond to the locomotor attenuating effects of the GHSR1a antagonist YIL781. The data presented here suggest that the separate stages of addictive behavior differ in their requirements for βarrestin-2 and show that pharmacological inhibition of βarrestin-2 function through GHSR1a antagonism is not equivalent to the loss of βarrestin-2 function achieved by genetic ablation. These data support targeting GHSR1a signaling in addiction therapy but indicate that using signaling biased compounds that modulate βarrestin-2 activity differentially from G protein activity may be required.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  YIL781; addiction; arrestin; cocaine; ghrelin

Mesh:

Substances:

Year:  2017        PMID: 28941296      PMCID: PMC5705267          DOI: 10.1002/syn.22012

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  34 in total

1.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

2.  Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite.

Authors:  Alfonso Abizaid; Zhong-Wu Liu; Zane B Andrews; Marya Shanabrough; Erzsebet Borok; John D Elsworth; Robert H Roth; Mark W Sleeman; Marina R Picciotto; Matthias H Tschöp; Xiao-Bing Gao; Tamas L Horvath
Journal:  J Clin Invest       Date:  2006-10-19       Impact factor: 14.808

3.  Discovery of ML314, a Brain Penetrant Non-Peptidic β-Arrestin Biased Agonist of the Neurotensin NTR1 Receptor.

Authors:  Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick R Maloney; Yujie Li; Monika Milewski; Palak Gosalia; Wilson Gray; Alka Mehta; Eliot Sugarman; Becky Hood; Eigo Suyama; Kevin Nguyen; Susanne Heynen-Genel; Stefan Vasile; Sumeet Salaniwal; Derek Stonich; Ying Su; Arianna Mangravita-Novo; Michael Vicchiarelli; Gregory P Roth; Layton H Smith; Thomas D Y Chung; Glen R Hanson; James B Thomas; Marc G Caron; Lawrence S Barak; Anthony B Pinkerton
Journal:  ACS Med Chem Lett       Date:  2013-07-20       Impact factor: 4.345

4.  Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons.

Authors:  Stephan Lammel; Elizabeth E Steinberg; Csaba Földy; Nicholas R Wall; Kevin Beier; Liqun Luo; Robert C Malenka
Journal:  Neuron       Date:  2015-01-21       Impact factor: 17.173

5.  Ghrelin receptor antagonism attenuates cocaine- and amphetamine-induced locomotor stimulation, accumbal dopamine release, and conditioned place preference.

Authors:  Elisabet Jerlhag; Emil Egecioglu; Suzanne L Dickson; Jörgen A Engel
Journal:  Psychopharmacology (Berl)       Date:  2010-06-19       Impact factor: 4.530

6.  Sites of action of ghrelin receptor ligands in cardiovascular control.

Authors:  Brid Callaghan; Billie Hunne; Haruko Hirayama; Daniela M Sartor; Trung V Nguyen; Fe C Abogadie; Dorota Ferens; Peter McIntyre; Kung Ban; Jonathan Baell; John B Furness; James A Brock
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-10       Impact factor: 4.733

7.  Systemic administration of ghrelin increases extracellular dopamine in the shell but not the core subdivision of the nucleus accumbens.

Authors:  Davide Quarta; Carla Di Francesco; Sergio Melotto; Laura Mangiarini; Christian Heidbreder; Gael Hedou
Journal:  Neurochem Int       Date:  2008-12-11       Impact factor: 3.921

Review 8.  Conditioned cues and the expression of stimulant sensitization in animals and humans.

Authors:  Paul Vezina; Marco Leyton
Journal:  Neuropharmacology       Date:  2008-07-09       Impact factor: 5.250

Review 9.  Dissecting components of reward: 'liking', 'wanting', and learning.

Authors:  Kent C Berridge; Terry E Robinson; J Wayne Aldridge
Journal:  Curr Opin Pharmacol       Date:  2009-01-21       Impact factor: 5.547

Review 10.  Determination of motor activity and anxiety-related behaviour in rodents: methodological aspects and role of nitric oxide.

Authors:  Natalia Sestakova; Angelika Puzserova; Michal Kluknavsky; Iveta Bernatova
Journal:  Interdiscip Toxicol       Date:  2013-09
View more
  4 in total

1.  β-Arrestin-Biased Allosteric Modulator of NTSR1 Selectively Attenuates Addictive Behaviors.

Authors:  Lauren M Slosky; Yushi Bai; Krisztian Toth; Caroline Ray; Lauren K Rochelle; Alexandra Badea; Rahul Chandrasekhar; Vladimir M Pogorelov; Dennis M Abraham; Namratha Atluri; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Patrick Maloney; Hong Yuan; Zibo Li; William C Wetsel; Anthony B Pinkerton; Lawrence S Barak; Marc G Caron
Journal:  Cell       Date:  2020-05-28       Impact factor: 41.582

2.  Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia.

Authors:  Cristina Torres-Fuentes; Elena Pastor-Cavada; Rafael Cano; Dalia Kandil; Rachel Shanahan; Rocio Juan; Hamdy Shaban; Gerard P McGlacken; Harriët Schellekens
Journal:  Int J Mol Sci       Date:  2018-05-30       Impact factor: 5.923

3.  Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand for modulating brain dopamine.

Authors:  J D Gross; D W Kim; Y Zhou; D Jansen; L M Slosky; N B Clark; C R Ray; X Hu; N Southall; A Wang; X Xu; E Barnaeva; W C Wetsel; M Ferrer; J J Marugan; M G Caron; L S Barak; K Toth
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-03       Impact factor: 12.779

Review 4.  Advances in the Development of Nonpeptide Small Molecules Targeting Ghrelin Receptor.

Authors:  Gianfabio Giorgioni; Fabio Del Bello; Wilma Quaglia; Luca Botticelli; Carlo Cifani; E Micioni Di Bonaventura; M V Micioni Di Bonaventura; Alessandro Piergentili
Journal:  J Med Chem       Date:  2022-02-14       Impact factor: 7.446

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.